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Abstract
Senescent cells (SCs) accumulate with age and after genotoxic stress, such as total-body 
irradiation (TBI)1–6. Clearance of SCs in a progeroid mouse model using a transgenic approach 
delays several age-associated disorders7, suggesting that SCs play a causative role in certain age-
related pathologies. Thus, a ‘senolytic’ pharmacological agent that can selectively kill SCs holds 
promise for rejuvenating tissue stem cells and extending health span. To test this idea, we screened 
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a collection of compounds and identified ABT263 (a specific inhibitor of the anti-apoptotic 
proteins BCL-2 and BCL-xL) as a potent senolytic drug. We show that ABT263 selectively kills 
SCs in culture in a cell type– and species-independent manner by inducing apoptosis. Oral 
administration of ABT263 to either sublethally irradiated or normally aged mice effectively 
depleted SCs, including senescent bone marrow hematopoietic stem cells (HSCs) and senescent 
muscle stem cells (MuSCs). Notably, this depletion mitigated TBI-induced premature aging of the 
hematopoietic system and rejuvenated the aged HSCs and MuSCs in normally aged mice. Our 
results demonstrate that selective clearance of SCs by a pharmacological agent is beneficial in part 
through its rejuvenation of aged tissue stem cells. Thus, senolytic drugs may represent a new class 
of radiation mitigators and anti-aging agents.
Previous efforts to identify small molecules that selectively kill SCs have yielded only two 
nonspecific and cell type–selective senolytic drugs8. To identify senolytic drugs that are 
more specific and have broader-spectrum activity, we took a targeted approach by 
individually titrating the cytotoxicity of a handful of small molecules that participate in 
pathways predicted to be important for the viability of SCs or for the maintenance of their 
phenotype (Supplementary Tables 1 and 2). We studied the effects of these compounds on 
human WI-38 fibroblasts, because this cell line has been extensively used to study 
replicative and stress-induced premature senescence in culture9,10. After incubation with the 
compounds, we assessed the survival of WI-38 cells that either were non-senescent or that 
had been induced to senesce by treatment with ionizing radiation (IR), replicative exhaustion 
or oncogenic Ras expression. Using this approach, we identified ABT263 as a potent 
senolytic drug that selectively, potently and rapidly kills SCs, regardless of how they were 
induced (Fig. 1a,b and Supplementary Fig. 1). In addition, ABT263 treatment was cytotoxic 
against SCs in a cell type– and species-independent manner: senescent human fibroblasts 
(IMR-90), human renal epithelial cells (RECs) and mouse embryo fibroblasts (MEFs) were 
more sensitive to ABT263 treatment than were their non-senescent counterparts (Fig. 1c).
To determine whether ABT263 is senolytic in vivo, we used sublethally irradiated p16-3MR 
transgenic mice. These mice carry a trimodal reporter protein (3MR) under the control of the 
cyclin-dependent kinase inhibitor 2a (Cdkn2a; also referred to as p16) promoter 
(Supplementary Fig. 2a)11. p16 is a widely used SC biomarker and a modulator of stem cell 
aging12–14. The 3MR-encoding transgene encodes a fusion protein consisting of Renilla 
luciferase (for bioluminescent imaging), monomeric red fluorescent protein (mRFP, for 
sorting and fluorescence microscopy) and herpes simplex virus thymidine kinase (HSV-TK, 
which converts ganciclovir (GCV) into a toxic DNA chain terminator to selectively kill 
HSV-TK–expressing SCs11). Therefore, p16-3MR mice can be used to identify, track and 
selectively kill p16+ SCs in vivo. By whole-body luminescence imaging, exposure of young 
(2-month-old) p16-3MR mice to a sub-lethal dose (6 Gy) of TBI induced a time-dependent 
increase in SC abundance (Supplementary Fig. 2b,c). Non-irradiated p16-3MR mice showed 
little SC accumulation (as determined by luminescence) up to 8 months of age (data not 
shown). These findings agree with observations that SCs are rare in normal mice before 40 
weeks of age, but rapidly accumulate after exposure to genotoxic insults12,13. After TBI, the 
lungs showed the greatest increase in SCs, and skeletal muscle and brain showed the next 
greatest increase; liver and heart showed minimal increases (Supplementary Fig. 2d,e). Two 
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GCV treatment cycles effectively cleared the SCs that had been induced by TBI of 
p16-3MR mice; notably, ABT263 treatment had a similar effect (Fig. 1d,e). SC clearance 
was confirmed by analyzing the lungs, in which GCV or ABT263 treatment not only 
reduced IR-induced SCs (Fig. 1f) but also suppressed the expression of several senescence-
associated secretory phenotype (SASP) factors15 (Fig. 1g). Thus, treatment with ABT263 
was as effective as treatment with GCV in clearing IR-induced SCs in irradiated p16-3MR 
mice.
ABT263 is a potent inducer of apoptosis in many types of tumor cells16. To determine 
whether ABT263 induces apoptosis in SCs, we assayed apoptosis in IR-induced WI-38 SCs 
after vehicle or ABT263 treatment in the presence or absence of the pan-caspase inhibitor 
Q-VD-OPh (QVD)17. The selective killing of SCs by ABT263 treatment was abrogated in 
the presence of QVD (Fig. 2a,b), indicating that ABT263 killing depends on the induction of 
apoptosis. QVD treatment also protected IR-induced senescent IMR-90 fibroblasts and 
RECs against ABT263 cytotoxicity (Supplementary Fig. 3a,b). Irradiated WI-38 cells 
acquired sensitivity to ABT263 only after they became fully senescent, as determined by 
expression of senescence-associated β-galactosidase (SA–β-gal) (Fig. 2c). This result 
indicates that senescence, rather than DNA damage per se, sensitizes cells to ABT263. 
ABT263 probably kills SCs through the intrinsic apoptotic pathway18,19, because treated 
SCs showed increased levels of activated caspase-3 but not of caspase-8 or receptor-
interacting protein (RIP) 1 (Fig. 2d,e).
To determine whether SCs are more sensitive to ABT263 than non-senescent cells owing to 
differential expression of anti- or pro-apoptotic proteins, as suggested by previous 
studies19,20, we measured the levels of these proteins in SCs. ABT263 sensitivity correlated 
with increased expression of anti-apoptotic BCL-xL and pro-apoptotic BAK, but not with 
increased expression of anti-apoptotic BCL-2 or the pro-apoptotic BAX, BAD, BID, BIM or 
NOXA proteins (Fig. 2f and Supplementary Fig. 3c,d). Inhibition of BCL-2 or BCL-xL 
function alone by treating cells with ABT199 (ref. 21) or WEHI539 (ref. 22), respectively, 
did not selectively kill SCs; however, treatment with the combination of ABT199 and 
WEHI539 did so (Fig. 2g and Supplementary Fig. 3e,f). This finding suggests that BCL-2 
and BCL-xL act in a redundant manner to protect SCs from apoptotic death, such that 
simultaneous inhibition of BCL-2 and BCL-xL activity is required to selectively induce SC 
apoptosis. Consistent with this idea, downregulation of BCL2 or BCL2L1 (which encode 
BCL-2 and BCL-xL, respectively) expression by using short hairpin RNAs (shR-NAs) 
specific for these transcripts had minimal effects on SC survival, but downregulation of both 
BCL2 and BCL2L1 expression selectively reduced SC viability (Fig. 2h).
Our previous studies4 showed that sublethal TBI induces long-term bone marrow injury that 
is manifested by a persistent decrease in HSC self-renewal and hematopoietic function. This 
effect is probably mediated by induction of HSC senescence, as HSCs from TBI-treated 
mice exhibited increases in mRNA expression of Cdkn1a (another commonly used 
biomarker for SCs) and Cdkn2a, an increase in SA–β-gal staining and a decrease in 
clonogenic activity (Supplementary Fig. 4). Senescent HSCs induced by IR treatment 
exhibited phenotypes similar to those seen in HSCs from aged animals, including decreases 
in self-renewal, clonogenicity and long-term repopulating ability, as well as myeloid 
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skewing4,23–26. Therefore, IR-induced long-term bone marrow injury can be considered to 
represent a model of premature aging of the hematopoietic system4,23–29. In addition, long-
term bone marrow injury in irradiated patients can promote, over time or after additional 
hematopoietic stress, hypoplastic anemia, myelodysplastic syndrome or leukemia30–32.
Using our sublethal TBI C57BL/6 mouse model4, we asked whether ABT263 treatment can 
effectively clear SCs, including senescent HSCs induced by IR treatment, and whether SC 
clearance can rejuvenate the prematurely aged hematopoietic system and/or mitigate IR-
induced long-term bone marrow injury. Bone marrow HSCs from irradiated control 
(vehicle-treated) mice showed significant increases in Cdkn2a mRNA and SA–β-gal levels, 
as compared to HSCs from sham-irradiated (Ctl) mice (Fig. 3a,b), indicating that sublethal 
TBI induces HSC senescence. As assessed by these markers, senescent HSCs were 
effectively cleared by ABT263 treatment. The clearance of senescent HSCs by treatment 
with ABT263 did not quantitatively reduce the percentages and numbers of HSCs and 
hematopoietic progenitor cells (HPCs) in the bone marrow (Supplementary Fig. 5). Instead, 
ABT263 treatment significantly improved the clonogenicity (Fig. 3c) and long-term 
engraftment ability of irradiated HSCs after transplantation into both primary and secondary 
recipients (Fig. 3d–f and Supplementary Fig. 6). In addition, ABT263 treatment (i) 
attenuated TBI-induced HSC myeloid skewing (Fig. 3e,f and Supplementary Fig. 6), a 
prominent aging phenotype; (ii) attenuated the disruption of HSC quiescence (as assessed by 
the percentage of HSCs in the G0 stage of the cell cycle), which can lead to premature 
exhaustion in HSCs; and (iii) reduced the numbers of HSCs with persistent DNA damage 
(Supplementary Fig. 7). The attenuation of myeloid skewing may be partly due to increased 
lymphopoiesis (Supplementary Fig. 8).
The mechanism by which ABT263 rejuvenates the prematurely aged hematopoietic system 
of irradiated mice appears to be primarily through the selective cytotoxicity of ABT263 
against senescent HSCs, because ABT263 treatment had selective cytotoxic effects in 
culture against HSCs isolated from mice treated with TBI but had no effect on HSCs from 
non-irradiated control mice (Supplementary Fig. 9a). We suggest that clearance of senescent 
HSCs by ABT263 treatment can promote the expansion of normal HSC clones that were 
either spared from or had repaired IR-induced damage and were thus able to expand into the 
vacated HSC niche. ABT263 treatment also abrogated the IR-induced SASP response in 
HSCs and bone stromal cells (Supplementary Fig. 9b,c)15,33; this effect on the SASP 
response may also contribute to the rejuvenation of HSCs after TBI by improving the bone 
marrow microenvironment. To more critically test the idea that rejuvenation of the 
hematopoietic system of irradiated mice by ABT263 treatment is mediated by SC clearance, 
we used GCV treatment to specifically deplete SCs in p16-3MR mice after they had been 
exposed to 6 Gy TBI, in a manner similarly to that of ABT263 administration to C57BL/6 
mice that had been treated with TBI (Fig. 3a,g). Depletion of SCs in irradiated p16-3MR 
mice by using GCV (Fig. 3g–j) phenocopied the findings for ABT263-treated TBI-exposed 
C57BL/6 mice (Fig. 3b–f,h–j), supporting the idea that the beneficial effects of ABT263 on 
the prematurely aged hematopoietic system induced by TBI treatment are mainly because of 
the killing of SCs.
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Similarly to its effects in TBI-treated mice, ABT263 treatment cleared SCs in normally aged 
mice (Fig. 4a). Treatment with ABT263 also significantly reduced age-related increases in 
the mRNA levels of Cdkn2a, Tnfa (which encodes tumor necrosis factor (TNF)-α) and Ccl5 
(which encodes the chemokine CCL5) in lungs (Fig. 4b). In mice, aging is associated with a 
qualitative, but not a quantitative, reduction in tissue stem cells, including HSCs and 
MuSCs, which has been attributed in part to stem cell senescence25,34. Although it is still a 
matter of intense debate whether HSCs senesce with age depending on p16 upregulation, 
HSCs from aged mice consistently exhibit defects in single-cell clonogenicity, long-term 
repopulating ability and balanced multilineage differentiation24,25. All these age-related 
HSC alterations were attenuated by ABT263 treatment, because HSCs from ATB263-treated 
aged mice showed a substantial improvement in clonogenic activity in culture, as compared 
to vehicle-treated aged mice, and were capable of long-term and multilineage engraftment 
after bone marrow transplantation (Fig. 4c,d and Supplementary Fig. 10). In addition, we 
studied the effects of ABT263 treatment on MuSCs isolated from the hind limb skeletal 
muscle of normally aged mice. ABT263 treatment of normally aged mice improved the 
clonogenicity of isolated MuSCs in culture, as compared to MuSCs isolated from vehicle-
treated aged mice (Fig. 4e–g). This improvement was associated with significant reductions 
in the number of MuSCs that stained positive for p16, phosphorylated p38 (p-p38+, a 
biomarker of senescent MuSCs) and the DNA damage marker γ-H2AX (Fig. 4e–j and 
Supplementary Fig. 11), which are considered to be senescent MuSCs34. These findings 
suggest that ABT263 treatment of normally aged mice clears senescent HSCs in the bone 
marrow and MuSCs in the skeletal muscle and rejuvenates the function of the remaining 
HSCs and MuSCs.
Collectively, our results show that ABT263 is a potent and broad-spectrum senolytic drug, 
with potential activity as a mitigator of radiation injury, particularly with respect to the late 
effects of IR that are associated with increases in SC abundance, such as IR-induced long-
term bone marrow injury. However, ABT263 has some toxic side effects35; in particular, 
transient thrombocytopenia and neutropenia are the common toxicities associated with 
ABT263 treatment in patients. Adverse drug effects are hurdles for anti-aging therapies that 
require long treatment intervals5,36. Therefore, it remains to be determined whether ABT263 
treatment can be used to delay aging or age-related diseases in normally aged experimental 
animals or in humans.
ONLINE METHODS
Cells
Human WI-38 (WI-38, catalog no. CCL-75) and IMR-90 fibroblasts (IMR-90, catalog no. 
CCL-186) and human renal epithelial cells (RECs, catalog no. PCS-400-012) were 
originally obtained from the American Type Culture Collection (Manassas, VA, USA). 
Mouse embryonic fibroblasts (MEFs) were isolated from mouse embryos as previously 
described37. All cells were cultured in a complete cell culture medium (CM) (Dulbecco’s 
Modified Eagle Medium supplemented with 10% FBS, 100 U/ml penicillin and 100 µg/ml 
streptomycin (all from Atlanta Biologicals, Norcross, GA, USA)) in a humidified incubator 
at 37 °C and 5% CO2. To avoid cells that were undergoing replicative senescence, low-
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passage WI-38 (<25 passages), IMR-90 (<25 passages), RECs (<25 passages), and MEFs 
(<3 passages) cells were used as normal controls or for the induction of senescence. To 
induce replicative senescence, WI-38 cells were routinely subcultured until they stopped 
dividing and became senescent, after approximately 38 passages or 60 population doublings 
(Supplementary Fig. 1a)38. To induce cellular senescence by ionizing radiation (IR), cells at 
about 70% confluence were exposed to 10 Gy of IR in a J.L. Shepherd Model Mark 
I 137Cesium γ-irradiator (J.L. Shepherd, Glendale, CA, USA) at a dose rate of 1.080 Gy/min. 
Three days after irradiation, cells were passaged once at a 1:3 dilution, and they became 
fully senescent 7 d after irradiation, as shown in Supplementary Figure 1a (ref. 38). To 
induce cellular senescence by ectopic expression of Ras, WI-38 cells were infected with 
retroviruses containing pBabe-H-Ras or the pBabe-puro control vector (Addgene, 
Cambridge, MA, USA)10,38. Two days after viral infection, transfected cells were selected 
by incubation with puromycin (2 µg/ml) (Invitrogen, Grand Island, NY, USA) for 5 d; Ras-
transfected cells but not control vector–transfected cells then became senescent 
(Supplementary Fig. 1a). Until they were used for experiments, SCs were maintained in 
culture for a few days (but <7 d) by changing the culture medium every 3 d.
Cell viability assays
Cells were seeded into wells of a 24- or 48-well plate. After overnight incubation, they were 
treated with vehicle (0.1% DMSO or PBS) or compounds (listed in Supplementary Tables 1 
and 2) at increasing concentrations and for various periods of times. The cells were digested 
with 0.25% trypsin and 1 mM EDTA, and harvested in PBS containing 2% FBS. After 
incubation with propidium iodide (PI, 100 ng/ml) in PBS at room temperature for 1 min, 
cells were centrifuged at 1,200 r.p.m. for 6 min to remove PI and then resuspended in PBS 
containing 2% FBS for analysis using a BD LSR II flow cytometer (BD Biosciences, San 
Jose, CA, USA). Viable cells (PI− cells) were analyzed by flow cytometry at a constant flow 
rate and calculated as a percentage of control cells treated with vehicle using the formula: 
percentage of control = (Ndrug/Nc) × 100, where Ndrug and Nc represent the absolute number 
of PI− viable cells for drug-treated and vehicle-treated cells, respectively.
Calculation of EC50 values
Dose-response curves were generated for each tested compound and the half-maximal 
inhibitory concentrations (EC50 values) were calculated by Probit analysis39.
SA–β-galactosidase staining, BrdU incorporation assays and apoptosis assays
SA–β-gal staining was done using a SA–β-gal staining kit (catalog no. 9860; Cell Signaling 
Technology, Danvers, MA, USA) according to the manufacturer’s instructions. SCs were 
identified as blue-stained cells under light microscopy. A total of 1,000 cells were counted 
in 20 random fields on a slide to determine the percentage of SA–β-gal+ cells38. Flow SA–β-
gal staining assay was performed by flow cytometry using an ImaGene Green C12FDG lacZ 
gene expression kit from Molecular Probes (Life Technologies, Carlsbad, CA), according to 
the manufacturer’s instructions and the protocols reported previously40.
A BrdU incorporation assay was used to determine cellular senescence as previously 
described41. Apoptosis was determined by flow cytometry as previously described4.
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Microscopy
Cells were viewed and photographed using an Axioplan research microscope (Carl Zeiss 
Inc., Jena, Germany) equipped with a 100-W mercury light source. Images were captured 
with a Dage CCD100 integrating camera (Dage-MTI, Michigan, USA) and a Flashpoint 128 
capture board (Integral Technologies, Indianapolis, Indiana, USA). The captured images 
were processed using Image Pro Plus software (Media Cybernetics, Rockville, Maryland, 
USA) and displayed with Adobe Photoshop V6.0.
Western blot analysis
Cells (1 × 106) were lysed in 100 µl lysis buffer (20 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 
mM EDTA, 1 mM EGTA, 10% glycerol, 1% NP-40, 0.1 M NaF, 1 mM DTT, 1 mM PMSF, 
1 mM sodium vanadate and 2 µg/ml leupeptin and aprotinin). An equal amount of protein 
(25–50 µg/lane) from each cell extract was resolved on a 12% SDS-PAGE gel. Proteins 
were blotted to a NOVEX NC membrane (Life Technologies) by electrophoresis. A mixture 
of the cell lysates from etoposide-treated Jurkat cells (prepared by the authors) and 
cytochrome c–treated Jurkat cells (obtained from Cell Signaling, Danvers, MA, USA) was 
used as a positive control for the blots presented in Figure 2d,e. The membranes were 
blocked with TBS-T blocking buffer (5% nonfat milk in 25 mM Tris-HCl pH 7.4, 3 mM 
KCl, 140 mM NaCl and 0.05% Tween) and subsequently probed with primary antibodies at 
a predetermined optimal concentration overnight at 4 °C or for 1 h at room temperature. 
After extensive washing with TBS-T, the membranes were then incubated with an 
appropriate peroxidase-conjugated secondary antibody (Jackson Immuno Research Europe, 
Suffolk, UK) for 1 h at room temperature. After three washes with TBS-T, the proteins of 
interest were detected using the ECL Western Blotting Detection Reagents (catalog no. 
WBKLS0100, EMD Millipore, Newmarket, Suffolk, UK) and recorded by exposure of the 
blots to X-ray film (Pierce Biotech, Rockford, IL, USA). Information on all antibodies used 
in western blot analyses is listed in Supplementary Table 3.
Knockdown of BCL2 and/or BCL2L1 with short hairpin RNAs (shRNAs)
Control lentiviral pLKO.1 vectors and pLKO.1 vectors containing shRNAs specific for 
human BCL2 (RHS4533–EG596) and BCL2L1 (RHS4533–EG598) were obtained from 
Thermo Fisher Scientific, Inc. (Waltham, MA, USA). Viral particles were produced as 
described above. To establish stable BCL2- and/or BCL2L1-knockdown WI-38 cell lines, 
WI-38 cells were infected twice with the viral particles under centrifugation (900g) at 32 °C 
for 30 min. Stably transduced cells were selected with puromycin (2 mg/ml). BCL2 and/or 
BCL2L1 knockdown was confirmed by western blot before the cells were used in an 
experiment.
Mice
Young (approximately 2-month-old) male C57BL/6J (CD45.2) mice and B6.SJL–
PtprcaPepcb/BoyJ (CD45.1) (a C57BL/6 congenic strain of mice used as recipients for 
BMT; Ptprc, protein tyrosine phosphatase receptor type C; Pepc, peptidase C) mice were 
purchased from Jackson Laboratory (Bar Harbor, MA, USA). p16-3MR transgenic mice 
were bred at the University of Arkansas for Medical Sciences’ (UAMS) Association for the 
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Assessment and Accreditation of Laboratory Animal Care International (AAALAC)-
certified animal facility as described previously11. Mice were randomly assigned to 4 or 5 
mice per cage, were housed at the UAMS AAALAC-certified animal facility and received 
food and water ad libitum. Aged male C57BL/6J mice (approximately 20 months old) were 
obtained from the aged-rodent colonies of the National Institute on Aging (https://
www.nia.nih.gov/research/scientific-resources#rodent). The mice were housed in the 
University of North Carolina at Chapel Hill’s (UNC) barrier facility on a standard diet along 
with a group of young male C57BL/6 mice as controls. The mice used for all of the 
experiments were randomly assigned to a treatment group. For animal studies, sample sizes 
were estimated according to our previous experience. Mice with tumors and/or leukemia 
were excluded from experiments and analyses. All animal work was approved and done in 
accordance with the UAMS and UNC Institutional Animal Care and Use Committees.
Total body irradiation (TBI) and treatment with ABT263 and ganciclovir (GCV)
Male C57BL/6J and p16-3MR transgenic mice at 2–3 months of age were exposed to sham 
irradiation as controls or a sublethal dose (6 Gy) of TBI in a J.L. Shepherd Model Mark 
I 137Cesium γ-irradiator (J.L. Shepherd) at a dose rate of 1.080 Gy/min. 8 or 16 weeks after 
TBI, mice were treated with vehicle (either PBS or ethanol:polyethylene glycol 400:Phosal 
50 PG (a standardized phosphatidylcholine (PC) concentrate with at least 50% PC and 
propylene glycol, Phospholipid Gmbh, Cologne, Germany) at 10:30:60), ABT263 (in 
ethanol:polyethylene glycol 400:Phosal 50 PG), or GCV (in PBS). ABT263 was 
administered to mice by gavage at 50 mg per kg body weight per day (mg/kg/d) for 7 d per 
cycle for two cycles with a 2-week interval between the cycles. GCV was administered to 
mice by intraperitoneal (i.p.) injection at 25 mg/kg/d for 5 d per cycle for two cycles with a 
2-week interval between the cycles. Luminescence imaging was performed on p16-3MR 
mice 1 d after the last treatment with vehicle, ABT263 or GCV, as described below. The day 
after imaging, mice were killed by CO2 suffocation followed by cervical dislocation. 
Various tissues were harvested for immediate tissue luminescence imaging, as described 
below, or for RNA extraction to analyze SASP. Groups of young C57BL/6 and p16-3MR 
transgenic mice were also killed 5 weeks after vehicle, ABT263 or GCV treatment to 
harvest bone marrow cells (BMCs) for the various assays described below. In addition, 
groups of young (2- to 3-month-old) and aged (21- to 22-month-old) male C57BL/6 and 
p16-3MR transgenic mice were treated with vehicle or ABT263 and analyzed as described 
above.
Bioluminescence assay
For measurement of in vivo luminescence, mice were injected i.p. with 250 µl of Xenolight 
RediJect Coelenterazine h (100 µg/ml, PerkinElmer, Waltham, MA, USA). Five minutes 
after the injection, mice were anesthetized with 4% isoflurane gas at 1 liter/min oxygen 
flow. Luminescence images were acquired using a Xenogen IVIS-200 Optical in vivo 
Imaging System equipped with Living Image Version 4.3.1 software (Caliper Life Sciences, 
Hopkinton, MA, USA). All image scans were acquired with an E field of view at 15–20 min 
after the injection; the mice were kept under 1.5% isoflurane gas at 1 liter/min oxygen flow.
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For tissue luminescence imaging, tissues harvested from euthanized mice were immediately 
soaked in prewarmed (37 °C) PBS with 2% FBS and a 1:10 dilution of Xenolight RediJect 
Coelenterazine h for 10 min. Tissues were then transferred into a new 35-mm dish, and 
luminescence images were acquired using a Xenogen IVIS-200 Optical in vivo Imaging 
System at 12–15 min after the tissue had been soaked in substrate solution.
Isolation of bone marrow mononuclear cells (BM-MNCs), lineage-negative hematopoietic 
cells (Lin− cells), HSCs and LT-HSCs
BMCs were harvested, bone marrow mononuclear cells (BM-MNCs) and lineage-negative 
hematopoietic (Lin−) cells were isolated, and HSCs (CD150+CD48−Lin−Sca1+c-Kit+, also 
referred to as CD150+CD48−LSK, cells) and LT-HSCs (CD34−CD48−CD155+ LSK cells) 
were sorted by an Aria II cell sorter (BD Biosciences) as described previously4. Information 
for all of the antibodies used in cell isolation and sorting is listed in Supplementary Table 4.
B cell analysis
BM-MNCs (1 × 106) were incubated with FITC-labeled anti-CD93, APC-labeled anti-IgM 
and PE-labeled anti-B220 at 4 °C for 30 min and then washed with PBS containing 0.25 
µg/ml PI. Various B cell populations were analyzed using a BD LSRII flow cytometer (BD 
Biosciences).
Colony-forming cell assay in single-HSC liquid culture
The assay was done as described previously4. Briefly, single HSCs were directly sorted into 
wells of round-bottom 96-well plates. They were cultured in RPMI 1640 culture medium 
supplemented with 10% FCS, 50 ng/ml of mSCF, mFlt-3, mTPO and mGM-CSF, 20 ng/ml 
of mouse interleukin (IL) 3, and 5 U/ml mEPO (Supplementary Table 2) in the absence or 
presence of 1.25 µM ABT263. Freshly prepared medium was added every 3 d. After 14 d of 
culture, the numbers of cells produced by each HSC were counted. Cells that produced more 
than 10,000 cells were scored as colony-forming cells.
Cobblestone area–forming cell (CAFC) assay
The CAFC assay for BMCs was done as described previously4,42. For the single-HSC 
CAFC assay, single LT-HSCs from young and aged C57BL/6 mice treated with vehicle or 
ABT263 were directly sorted into wells of round-bottom 96-well plates containing FBMD-1 
stromal cells. CAFCs were scored by bright-field microscopy after 5–8 weeks of incubation 
as described previously24.
Competitive repopulation assay (CRA) and serial bone marrow transplantation (BMT)
CD45.2 mice were exposed to a sublethal dose (6.0 Gy) of TBI or sham irradiation and then 
treated with vehicle or ABT263 as shown in Figure 3a,g. BMCs were isolated and mixed 
with 2 × 105 competitive BMCs pooled from three CD45.1 mice. The cell mixture was then 
transplanted into lethally irradiated (9.5 Gy TBI) CD45.1 recipients via retro-orbital 
injection of the venous sinus. For the normal aging study, 50 freshly sorted LT-HSCs from 
young and aged C57BL/6 mice treated with vehicle or ABT263 were mixed with 3 × 105 
competitive BMCs pooled from three CD45.1 mice, and the cell mixture was then 
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transplanted into lethally irradiated CD45.1 recipients via retro-orbital injection of the 
venous sinus. Donor-cell engraftment in the recipients was analyzed at various times after 
transplantation as previously described4,42. For secondary BMT, 1 × 106 BMCs were 
harvested from each primary recipient 4 months after primary BMT and were then 
transplanted into a lethally irradiated recipient as described above. Donor-cell engraftment 
in both primary and secondary recipient peripheral blood was analyzed as previously 
described4,42.
Cell cycle and DNA damage analysis
Lin− cells were stained with antibodies against various HSC cell-surface markers and then 
fixed and permeabilized using Fixation-Permeabilization Solution (BD-Pharmingen, San 
Diego, CA). Subsequently, the cells were stained with anti-Ki67-FITC, anti–phospho–
histone H2AX (γ-H2AX) (Ser139)–Alexa Fluor 647, and 7-aminoactinomycin D (7-AAD) 
and then analyzed by flow cytometry as previously described4.
Isolation of bone stromal cells
Femur, tibia and pelvic bones were harvested from euthanized mice and cleaned by 
removing surrounding tissue and by flushing out bone marrow cells. The bones were cut into 
small (<1-mm long) pieces using scissors and then digested with 0.1% collagenase I and 15 
µg/ml DNAse I (Sigma, St. Louis, MO, USA) in PBS with 15% FBS at 37 °C for 1 h. Cells 
were collected after removing bone debris and filtering through a 40-µm filter. 
CD45−Lin−PI− bone stromal cells were harvested by cell sorting after staining with APC-
conjugated anti-CD45, biotin-conjugated anti-CD11b, CD3ε, Gr-1, B220 and Ter119, FITC-
conjugated streptavidin and PI.
Isolation of muscle stem cells (MuSCs)
Skeletal muscles, harvested from the hind legs of mice after euthanization, were torn into 
small pieces with forceps and were then digested with 0.2% type II collagenase in F10 
medium containing 10% horse serum (Thermo Fisher Scientific) for 90 min at 37 °C. After 
washing three times with PBS, single myofibers were digested further with 0.1% type II 
collagenase and 0.05% dispase (Thermo Fisher Scientific) in PBS for 30 min at 37 °C to 
separate myofiber-associated cells (containing MuSCs) from myofibers. Myofiber-
associated cells were filtered through a 70-µm cell strainer (Thermo Fisher Scientific), 
harvested by centrifugation (500g, 8 min), and stained with antibodies to CD45, Mac1, 
Sca1, CXCR4 and β1-integrin for cell sorting and analysis as described previously43,44. 
Information for all of the antibodies used for staining is provided in Supplementary Table 4.
Myogenic colony-forming cell assay for MuSCs
Single MuSCs were deposited into wells of collagen- and laminin-precoated 96-well plates 
(Corning Inc., NY, USA) at 1 cell per well by an Aria II cell sorter (BD Biosciences), as 
described previously43,44. The cells were cultured in F10 medium supplemented with 20% 
horse serum and 5 µg/ml basic fibroblast growth factor (bFGF; Thermo Fisher Scientific) 
and were fed every day with freshly prepared bFGF. Wells containing myogenic colonies 
were scored by bright-field microscopy after 6 d of culture to determine the number of 
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primary myogenic colony-forming cells (MCFCs)43,44. Cells were harvested from individual 
wells containing myogenic colonies, diluted 1:5 with F10 medium supplemented with 20% 
horse serum and 5 µg/ml bFGF, and then reseeded into five wells of collagen- and laminin-
precoated 96-well plates for quantification of secondary MCFCs in a manner similar to that 
for primary MCFCs.
Analysis of senescent MuSCs by p38 phosphoflow assay
Myofiber-associated cells were stained with antibodies against various MuSC surface 
markers, fixed and permeabilized using Fixation-Permeabilization Solution (BD-
Pharmingen), as shown in Figure 4e. Subsequently, the cells were stained with anti-p-p38 
(#4551; Cell Signaling, Danvers, MA, USA) and analyzed by flow cytometry.
Analysis of Pax7, p16 and g-H2AX expression in MuSCs by immunostaining
Approximately 2,000 freshly sorted MuSCs were spun on a slide for immunostaining by 
cytospin. After fixation with 4% paraformaldehyde (PFA) for 15 min at room temperature, 
cells were incubated in 0.1% Triton X-100 at room temperature for half an hour. After 
washing with PBS and a 60-min incubation in PBS with 1% bovine serum albumin, cells 
were incubated overnight at 4 °C with antibodies to p16, γ-H2AX or Pax7 (Supplementary 
Table 4), and then incubated with the corresponding secondary antibodies, with extensive 
washing between each step. The nuclear DNA of the cells was counterstained with DAPI 
(Sigma, St. Louis, MO, USA). The cells were viewed and photographed using an Axioplan 
research microscope as described above. A total of more than 100 cells per slide were 
counted in >30 random fields on a slide to determine the percentage of p16+ cells and the 
number of γ-H2AX foci for calculation of the average number of γ-H2AX foci/cell.
Quantitative PCR (qPCR)
Total cellular RNA was extracted and reverse transcription was performed as described 
previously4. To measure CDKN2A and Cdkn2a mRNA expression in WI-38 cells and mouse 
tissue, respectively, qPCRs were run with TaqMan qPCR reagents and primers 
(Supplementary Table 5) from Applied Biosystems. Human GAPDH and mouse Hprt were 
used as internal controls. Briefly, 1 µl cDNA was mixed with 10 µl TaqMan Universal 
Mastermix (Invitrogen) and 1 µl of TaqMan primers. Samples were added to 8 µl of water 
(for a total volume of 20 µl) and used for qPCR (50 °C for 2 min, 95 °C for 10 min, 40 × (95 
°C for 15 s and 60 °C for 1 min)). All reactions were run in triplicate on an ABI 
StepOnePlus Real-Time PCR System (Applied Biosystems).
To measure CDKN1A and GAPDH mRNA expression in WI-38 cells and Cdkn1a and SASP 
gene expression (including Il1a, Il1b, Il6, Tgfb1, Tnfa, Ccl5 and Cxcl10 mRNA) in mouse 
tissues, bone marrow HSCs and bone stromal cells, the SYBR assay kit was used (Applied 
Biosystems). Briefly, 1 µl cDNA was mixed with 7.5 µl SYBR Green PCR Master Mix and 
0.2 µl of primers (Supplementary Table 5). Samples were then added to 6.30 µl of water (for 
a total volume of 15 µl). qPCR conditions were as follows: 95 °C for 10 min, 40 × (95 °C for 
15 s and 60 °C for 1 min), 95 °C for 15 min, 60 °C for 60 min, 95 °C for 15 min. All 
reactions were run in triplicate on an ABI StepOnePlus Real-Time PCR System.
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Statistical analysis
The data displayed normal variance. No statistical method was used to predetermine sample 
size. The experiments were not randomized, except for the in vivo animal studies with mice 
as described above. The investigators were not blinded to allocation during experiments and 
outcome assessment. The data were analyzed by analysis of variance (ANOVA) using 
GraphPad Prism from GraphPad Software (San Diego, CA). In the event that ANOVA 
justified post hoc comparisons between group means, these were conducted using Neuman-
Keuls or Tukey’s multiple-comparisons test. P < 0.05 was considered to be significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
ABT263 has senolytic activity in cell culture and mice. (a) Quantification of viable WI-38 
non-senescent cells (NC), IR-induced senescent cells (IR-SC), replication-exhausted 
senescent cells (Rep-SC) or Ras-induced senescent cells (Ras-SC; in which oncogenic Ras is 
ectopically expressed) 72 h after treatment with increasing concentrations of ABT263 (n = 
3–6 for NC and IR-SC; n = 3 for Rep-SC; n = 4 for Ras-SC). (b) Quantification of viable 
IR-SCs at the indicated times after treatment of the IR-SCs with 1.25 µM ABT263 (left) or 
after the cells had been incubated with 1.25 µM ABT263 for the indicated amounts of time 
followed by removal of the drug and a further culture period of 72 h (right) (n = 3). (c) 
Quantification of viable non-senescent (NC) and IR-induced senescent (IR-SC) human 
IMR-90 fibroblasts (IMR-90), human renal epithelial cells (REC) and mouse embryonic 
fibroblasts (MEF) 72 h after treatment with increasing concentrations of ABT263 (n = 3 per 
group). (d) Experimental design for e–g. Sham-irradiated (Ctl) and TBI-treated young male 
p16-3MR mice were administered vehicle (Veh), ganciclovir (GCV) or ABT263 (ABT) and 
analyzed as indicated. I.p., intraperitoneal injection; p.o., oral administration. (e) Left, 
representative luminescence images of Ctl and TBI mice after treatment with vehicle, GCV 
or ABT263. Right, quantification (in arbitrary units, a.u.) of whole-body luminescence (Ctl 
mice: vehicle-treated, n = 6; GCV-treated, n = 4; ABT263-treated, n = 6; TBI mice: vehicle-
treated, n = 8; GCV-treated, n = 4; ABT263-treated, n = 7). A wild-type C57BL/6 mouse 
(WT) was included as a negative control. The vertical color bar indicates luminescence-
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signal strength. Scale bars, 15 mm. (f) Quantification of luminescence in lungs of Ctl or TBI 
mice treated as indicated (n = 5 per group). (g) Quantification of mRNA expression for 
Cdkn2a, Il1a, Tnfa, Ccl5 and Cxcl10 in lungs from Ctl or TBI mice treated as indicated (n = 
4 per group). Throughout, data are means ± s.e.m. **P < 0.01, ***P < 0.001 and ****P < 
0.0001 versus without ABT263 for a (one-way analysis of variance (ANOVA)); versus NC 
treated with the same concentrations of ABT263 for c; versus Ctl for e–g; two-way ANOVA 
for c–g.
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Figure 2. 
ABT263 kills SCs by apoptosis. (a) Representative flow cytometric plots to measure 
apoptosis (left) and quantitation of the percentage of viable (gate II: PI−annexin V−) and 
apoptotic (gates III and IV: PI−annexin V+ and PI+annexin V+) (right) cells of WI-38 IR-SC 
24 h after treatment with vehicle (Veh), 1.25 µM ABT263, 20 µM Q-VD-Oph (QVD), or the 
combination of ABT263 and QVD. (b) Quantification of the percentage of viable IR-SC 72 
h after treatment with vehicle or ABT263 ± QVD as in a. (c) Quantification of SA–β-gal+ 
cells (white bars) 10 d after exposure to increasing doses of IR (left) or after increasing 
periods of time after treatment with 10 Gy IR (right), and the viability of the irradiated cells 
under these conditions after an additional incubation with 1.25 µM ABT263 for 72 h (gray 
bars). (d) Representative western blot analysis of procaspase-8 (Procasp-8), cleaved 
caspase-8 (cCasp-8), RIP1, cleaved RIP1 (cRIP1) and β-actin in NC and IR-SC 24 h after 
incubation with vehicle or 1.25 µM ABT263 (ABT). (e) Top, representative western blot 
analysis of procaspase-3 (Procasp-3), cleaved caspase-3 (cCasp-3) and β-actin in NC and 
IR-SC from d. Bottom, normalized expression of Procasp-3 and cCasp-3 in NC and IR-SC. 
Because the samples used for the western blots in d,e were the same, the same β-actin blot 
was used as a control for both panels. A mixture of cell lysates from etoposide- or 
cytochrome c–treated Jurkat cells was used as a positive control (Ctl) for detection of 
cCasp-3 and cCasp-8. (f) Normalized expression of BCL-2, BCL-xL, BAK and BAX in 
WI-38 cells by western blot analysis at increasing times after treatment with IR (10 Gy). (g) 
Quantification of NC (left) and IR-SC (right) viability 72 h after incubation with vehicle, 2.5 
µM ABT199, 0.625 µM WEHI539, or the combination of ABT199 and WEHI539. (h) 
Quantification of NC and IR-SC viability 72 h after transfection with a control shRNA (Ctl) 
or shRNAs specific for BCL2, BCL2L1, or both BCL2 and BCL2L1. Throughout, data are 
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means ± s.e.m. of three experiments, except for h (n = 5). *P < 0.05, **P < 0.01, ***P < 
0.001 and ****P < 0.0001; one-way ANOVA for c,f; two-way ANOVA for b,e,g,h.
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Figure 3. 
SC clearance by treatment with ABT263 or GCV rejuvenates HSCs after TBI. (a) 
Experimental design for b–f. Sham-irradiated (Ctl) and TBI-treated young male C57BL/6 
mice were administered vehicle (Veh) or ABT263 (ABT) and analyzed as indicated. (b,c) 
Quantification of changes in Cdkn2a mRNA levels (b, left; n = 3 biological replicates) and 
the percentage of SA–β-gal+ cells (b, right; n = 4 mice per group) in sorted HSCs, and the 
number of day 35 cobblestone area–forming cells (CAFCs) in bone marrow cells (BMCs; c; 
n = 4 mice per group). #P < 0.05 versus Ctl mice; &P < 0.05 versus vehicle-treated TBI 
mice; two-way ANOVA; n.d., not detectable. (d) Scheme for competitive and serial bone 
marrow transplantation (BMT; see Online Methods for details). (e,f) Representative flow 
cytometry plots (e) and quantification (f) of donor-derived total white blood cells (CD45.2+; 
e, top; f, top left), and T cells (T; CD45.2+Thy-1.2+), B cells (B; CD45.2+B220+) and 
myeloid cells (M cells; CD45.2+CD11b/Gr-1+) (e, bottom; f) in the peripheral blood (PB) of 
recipient mice after primary BMT (n = 6 recipients per group). Donor-cell engraftment in 
the PB of secondary recipients is shown in Supplementary Figure 6. (g) Experimental design 
for h–j. Sham-irradiated (Ctl) and TBI-exposed young male p16–3MR mice were treated 
with vehicle or GCV and analyzed as indicated. (h) Quantification of the percentages of 
SA–β-gal+ cells in sorted HSCs from mice treated as outlined in g (Ctl mice: vehicle-treated, 
n = 7; GCV-treated, n = 7; TBI mice: vehicle-treated, n = 11; GCV-treated, n = 12). (i) 
Quantification of the number of day 35 CAFCs in BMCs (Ctl mice: vehicle-treated, n = 3; 
GCV-treated, n = 3; TBI mice: vehicle-treated, n = 7; GCV-treated, n = 6). (j) 
Quantification of the percentages of donor-derived total cells, T cells, B cells and M cells in 
the PB of primary recipients (Ctl donors: vehicle-treated, n = 3 recipients; GCV-treated, n = 
5 recipients; TBI donors: vehicle-treated, n = 7 recipients; GCV-treated, n = 9 recipients). 
Throughout, data are means ± s.e.m. In f,j, #P < 0.05 versus recipients of donor-derived cells 
from Ctl mice; &P < 0.05 versus recipients of donor-derived cells from vehicle-treated TBI 
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mice; in h,i, #P < 0.05 versus Ctl mice; &P < 0.05 versus vehicle-treated TBI mice; two-way 
ANOVA; n.d., not detectable.
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Figure 4. 
SC clearance by ABT263 treatment rejuvenates HSCs and MuSCs in normally aged mice. 
(a) Representative whole-body luminescent images (left) and quantification of luminescence 
(right) 1 d after 21- to 22-month-old male p16-3MR mice (aged) received vehicle (Veh; n = 
7) or ABT263 (ABT; n = 8), according to the scheme shown in Figure 3a. 2-month-old male 
p16-3MR mice (young; n = 5) without treatment and a WT C57BL/6 mouse were used as 
controls. The vertical color bar indicates luminescence-signal strength. #P < 0.05 versus 
young mice, &P < 0.05 versus vehicle-treated aged mice; unpaired Student’s t-test. Scale 
bars, 15 mm. (b–j) Aged (21- to 22-month-old) male C57BL/6 mice received vehicle (Veh) 
or ABT263 (ABT) according to the scheme shown in Figure 3a and were analyzed 1 week 
after the treatment; 2-month-old male C57BL/6 mice without treatment (young) were used 
as controls. (b) Quantification of changes in mRNA levels of Cdkn2a, Tnfa and Ccl5 in the 
lungs of aged (Veh, n = 11; ABT, n = 10) and young (n = 9) mice. (c) Scheme for 
competitive and serial BMT using sorted long-term HSCs (LT-HSCs; 
CD34−CD48−CD150+Lin−Sca1+c-Kit+). (d) Quantification of the percentages of donor-
derived total cells, T cells, B cells and M cells in the PB of primary recipients (recipients of 
donor cells from: young, n = 11; vehicle-treated aged, n = 15; ABT263-treated aged, n = 13; 
from two independent BMT experiments). Donor cell engraftment in the PB of secondary 
recipients is shown in Supplementary Figure 10c. (e) Gating strategy for analysis and 
isolation of MuSCs by flow cytometry (top) and representative micrographs showing 
immunostaining for the myogenic transcription factor Pax7 (a biomarker for MuSCs) 
(bottom). IF, immunofluorescence; MCFC, myogenic colony-forming cell. Scale bars, 20 
µm. (f) Quantification of MuSCs in muscle tissue. (g) Quantification of primary (left) and 
secondary (right) MCFCs in sorted MuSCs. (h,i) Quantification of p16+ cells (h) and 
phosphorylated p38+ (p-p38+) (i) cells in MuSCs. (j) Quantification of the average number 
of γ-H2AX foci in MuSCs. n = 5, 6, and 6 mice per group for Young, Aged + Veh, and 
Aged + ABT, respectively, for f,h,i,j; 8, 12, and 13 mice per group for g. Throughout, data 
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are means ± s.e.m. In d, #P < 0.05 versus recipients of donor cells from young mice, &P < 
0.05 versus recipients of donor cells from vehicle-treated aged mice; in g–j, #P < 0.05 versus 
young mice, &P < 0.05 versus vehicle-treated aged mice; unpaired Student’s t-test.
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